NCT07116486招募中1 期
Phase 1, Single-site, Single-arm, Clinical Imaging, and Blood-based Biomarker Trial Utilizing 18F-FSPG PET to Guide Therapy in Hepatocellular Carcinoma
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Safety and Adverse Events (AEs)
研究概览
简要总结
To evaluate the relationship between 18F-FSPG uptake in HCC lesions, ctDNA in blood and clinical response to Y90 radioembolization therapy in patients with hepatocellular carcinoma (HCC) by SOC imaging.
详细描述
Primary Objectives:
- To establish whether pre-treatment 18F-FSPG can be utilized as an imaging marker to predict response/resistance to Y90 treatment,
- To determine whether there is a correlation between change in 18F-FSPG uptake in HCC lesions and change in levels of ctDNA in the blood prior to and post-Y90 radioembolization and response to treatment as assessed by SOC imaging at 3-, 6-, 9-, and 12-months following the procedure.
Secondary Objectives:
- To determine if 18F-FSPG PET can visualize residual disease,
- To determine if ctDNA can detect residual disease,
- To determine the concordance of tumor detection by 18F-FSPG PET/CT imaging and SOC imaging.
- To establish whether 18F-FSPG uptake and levels of ctDNA can be utilized as imaging and bloodbased markers, respectively, to inform the response to therapy or lack thereof earlier than SOC imaging.
- To evaluate the relationship between 18F-FSPG PET, ctDNA, and SOC imaging to TTP or PFS.
- To evaluate voxel-wise relationships between 18F-FSPG intra-tumoral accumulation and SOC imaging.
- To evaluate the treatment response using the mRECIST and LI-RADS criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of HCC with one or more of the following:
- •Liver mass with non-rim arterial phase hyperenhancement (APHE) and one of the following:
- •10-19 mm with ≥ 2 additional major features according to LI-RADS criteria ("washout", enhancing "capsule", and/or threshold growth),
- •10-19 mm with "washout" and visibility at antecedent ultrasound (US) but with no "capsule" or threshold growth,
- •10-19 mm with ≥50% size increase in ≤6 months but with no "washout" or "capsule" or
- •≥20 mm with ≥1 additional major feature according to LI-RADS criteria ("washout", enhancing "capsule", or threshold growth).
- •Lesions that meet LI-RADS 4 criteria or
- •Lesions that meet LI-RADS 5 criteria or
- •Suggestive imaging findings plus Alpha Fetoprotein (AFP) > 200 mg/dL or
- •Tumor confirmed by arteriography or
- •Pathologic confirmation of tumor and
- •Patients with HCC must be a candidate for Y90 radioembolization monotherapy. and
- •Each patient must have completed conventional imaging and staging and CT before initiation of the investigational PET studies.
- •Age ≥18 years. Because no dosing or adverse event data are currently available on the use of 18F-FSPG in patients <18 years of age, children are excluded from this study.
- •The effects of 18F-FSPG on the developing human fetus are unknown. For this reason women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:
- •Postmenopausal (no menses in greater than or equal to 12 consecutive months).
- •History of hysterectomy or bilateral salpingo-oophorectomy.
- •Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
- •History of bilateral tubal ligation or another surgical sterilization procedure.
- •Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
- •Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of 18F-FSPG administration.
- •Ability to understand and the willingness to sign a written informed consent document
排除标准
- •Patients under the age of 18 will be excluded from the this study.
- •Patients who have HCC but are not candidates for Y90 radioembolization monotherapy.
- •Pregnant and breastfeeding patients. Pregnant women are excluded from this study because 18F-FSPG as a radiotracer has a potential teratogenic or abortifacient effect. Because there is an unknown but potential risk for adverse events in nursing infants secondary to administration of the tracer 18F-FSPG to the mother, breastfeeding should be discontinued.
- •Patients with poorly controlled diabetes mellitus (fasting blood glucose level > 200 mg/dL).
- •Patients with psychiatric illness/social situations that would limit compliance with study requirements.
- •Patients who have not recovered from AEs or had allergic reactions to similar compounds should be excluded.
研究组 & 干预措施
Single Arm
Experimental
Participants will be scheduled for a baseline investigational 18F-FSPG PET/CT scan within 4 weeks of SOC CT and no more than 2 weeks prior to Y90 treatment.
干预措施: Radiopharmaceutical 18F-FSPG (Diagnostic Test)
结局指标
主要结局
Safety and Adverse Events (AEs)
时间窗: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
18F-FDGal PET/CT and PET/MRI in Patients With Hepatocellular CarcinomaHepatocellular CarcinomaNCT05871892University of Aarhus125
Unknown
不适用
Contribution of F-18 Fluoro-Deoxy-Glucose PET/CT (Positron Emission Tomography) to the Assessment of HCC (Hepato-cellular Carcinoma) Treatment EfficiencyHepatocellular CarcinomaNCT01322477Hadassah Medical Organization25
终止
不适用
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal CancerEsophageal CarcinomaNCT06549413M.D. Anderson Cancer Center9
已完成
不适用
Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of MalignancyNeoplasmsNCT00725387Stanford University214
已完成
不适用
Relationship between FDG PET finding and oncologic gene mutation in hepatic/cholangic/pancreatic tumorsmalignant tumor of liver, bile duct system and pancreas.JPRN-UMIN000015737Atomic bomb disease institute, Nagasaki University48